Orano Med
Thomas Priem has a background in chemistry and pharmaceuticals, with experience in quality production, research and development, and teaching. Currently, Thomas holds a position as a Responsable d'installations at Orano Med, where Thomas manages teams, ensures operations run smoothly, and compliance with regulations. With a Doctorate in Chemistry Organic/Radiochemistry, Thomas has a strong foundation in the field and has held various roles in reputable companies such as SANOFI and Advanced Accelerator Applications. Thomas is skilled in managing production teams, overseeing equipment maintenance, and collaborating with other entities on site.
This person is not in any offices
Orano Med
1 followers
Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope. Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer. The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products. For more information please visit www.macrocyclics.com.